Vaxxinity to present clinical and preclinical pipeline data at ad/pd 2024

Cape canaveral, fla., feb. 13, 2024 (globe newswire) -- vaxxinity, inc. (nasdaq: vaxx), a u.s. company pioneering the development of a new class of medicines, today announced it will present clinical data from its ub-312 program in parkinson's disease and preclinical data from its anti-tau program in alzheimer's disease at the international conference on alzheimer's and parkinson's diseases and related neurological disorders (ad/pd 2024), taking place march 5-9, 2024 virtually and in lisbon, portugal.
VAXX Ratings Summary
VAXX Quant Ranking